The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients

[11] Keppler D(1997)Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography J Chromatogr B Biomed Sci Appl 693 437-441

[12] König J(2009)Pharmacogenetic pathway analysis of docetaxel elimination Clin Pharmacol Ther 85 155-163

[13] Amirimani B(2001)Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects Clin Pharmacol Ther 69 169-174

[14] Ning B(2004)ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition Clin Cancer Res 10 5889-5894

[15] Deitz AC(2006)Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel Clin Cancer Res 12 5786-5793

[16] Kuehl P(2007)A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871 Clin Cancer Res 13 3302-3311

[17] Zhang J(2006)Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms Clin Pharmacol Ther 79 570-580

[18] Lin Y(2004)CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer Cancer Res 64 8461-8467

[19] Hoffmeyer S(2008)ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel Clin Cancer Res 14 4543-4549

[20] Burk O(2008)Rhodamine 123 efflux in human subpopulations of hematopoietic stem cells: comparison between bone marrow, umbilical cord blood and mobilized peripheral blood CD34+ cells Int J Mol Med 22 237-242

[11] Keppler D(1997)Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography J Chromatogr B Biomed Sci Appl 693 437-441

[12] König J(2009)Pharmacogenetic pathway analysis of docetaxel elimination Clin Pharmacol Ther 85 155-163

[13] Amirimani B(2001)Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects Clin Pharmacol Ther 69 169-174

[14] Ning B(2004)ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition Clin Cancer Res 10 5889-5894

[15] Deitz AC(2006)Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel Clin Cancer Res 12 5786-5793

[16] Kuehl P(2007)A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871 Clin Cancer Res 13 3302-3311

[17] Zhang J(2006)Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms Clin Pharmacol Ther 79 570-580

[18] Lin Y(2004)CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer Cancer Res 64 8461-8467

[19] Hoffmeyer S(2008)ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel Clin Cancer Res 14 4543-4549

[20] Burk O(2008)Rhodamine 123 efflux in human subpopulations of hematopoietic stem cells: comparison between bone marrow, umbilical cord blood and mobilized peripheral blood CD34+ cells Int J Mol Med 22 237-242